Literature DB >> 3665846

Inhibition by melittin and fluphenazine of melanotropin receptor function and adenylate cyclase in M2R melanoma cell membranes.

J E Gerst1, Y Salomon.   

Abstract

Melanotropin (MSH) receptor activity in the M2R mouse melanoma cell line is tightly controlled by calcium by an unknown mechanism. The possibility that calcium regulation is mediated by calmodulin or a calmodulin-related calcium binding protein has been addressed in this report by studying the effects of two known calmodulin antagonists, fluphenazine and melittin, on MSH receptor function. Stimulation of adenylate cyclase (AC) in M2R plasma membranes by beta MSH was strongly inhibited by both antagonists. The concentrations of fluphenazine and melittin yielding half-maximal inhibition (IC50) of AC were 16 microM and 2.4 microM, respectively. Both fluphenazine and melittin also inhibit prostaglandin E1-, GTP gamma S, and forskolin-stimulated AC activity, as well as that of unstimulated enzyme, although inhibition is shown to occur at significantly higher concentrations of antagonist. We have shown that the calcium-dependent rate-limiting step in MSH stimulation of adenylate cyclase, that of hormone binding, is strongly inhibited by these antagonists at concentrations identical to, if not lower than, those required for the inhibition of AC activity (fluphenazine-IC50, 14 microM; melittin-IC50, 0.7 microM). The actions of these antagonists, furthermore, appear to be calcium insensitive, as melittin affects the stability of both the high affinity (calcium containing) and low affinity (calcium depleted) receptor-MSH complexes. The sensitivity of the MSH receptor to inhibition by calmodulin antagonists resembles that described for purified calmodulin-sensitive enzyme systems, which suggests a possible role for calmodulin in MSH receptor function. Among peptide hormone receptors, this effect by calmodulin antagonists appears to be unique for the MSH receptor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665846     DOI: 10.1210/endo-121-5-1766

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

Review 1.  Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy.

Authors:  Islam Rady; Imtiaz A Siddiqui; Mohamad Rady; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2017-05-20       Impact factor: 8.679

Review 2.  Mechanism of action of melanocortin peptides. Possible role in astrocyte regulation.

Authors:  M Zohar; Y Salomon
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

Review 3.  Helminthes and insects: maladies or therapies.

Authors:  Nora L El-Tantawy
Journal:  Parasitol Res       Date:  2014-12-30       Impact factor: 2.289

4.  Neuroprotective effects of melanocortins in experimental spinal cord injury. An experimental study in the rat using topical application of compounds with varying affinity to melanocortin receptors.

Authors:  H S Sharma; A Skottner; T Lundstedt; M Flärdh; L Wiklund
Journal:  J Neural Transm (Vienna)       Date:  2006-04       Impact factor: 3.575

Review 5.  Three valuable peptides from bee and wasp venoms for therapeutic and biotechnological use: melittin, apamin and mastoparan.

Authors:  Miguel Moreno; Ernest Giralt
Journal:  Toxins (Basel)       Date:  2015-04-01       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.